Agios Pharmaceuticals, Inc.
- Last sale
- Oct 1, 2026 · -2.45%
- Market cap
- $1.94B
- 59.78M shares
- Filings
- 1,028
Q3 2026+48.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+16.9% FY25 yoy
- $1.94B
- —
- 13.8×
- 2.0×
- -17.32%
- —
Twelve months to Sep 30, 2026 · derived
Price
Oct 1, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $54,028,000 | reported | |
| FY 2024 | 2024-12-31 | $36,498,000 | reported | |
| FY 2023 | 2023-12-31 | $26,823,000 | reported | |
| FY 2022 | 2022-12-31 | $14,240,000 | reported | |
| FY 2021 | 2021-12-31 | $0 | reported | |
| FY 2020 | 2020-12-31 | $0 revised | reported | |
| FY 2019 | 2019-12-31 | $117,912,000 | reported | |
| FY 2018 | 2018-12-31 | $94,387,000 | reported | |
| FY 2017 | 2017-12-31 | $43,011,000 | reported | |
| FY 2016 | 2016-12-31 | $69,892,000 | reported | |
| FY 2015 | 2015-12-31 | $59,119,000 | reported | |
| FY 2014 | 2014-12-31 | $65,358,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2023 | — | $0.00 | $0.00 | — | 56.19M sh | +1.6% | — |
| FY2022 | — | $0.00 | $0.00 | — | 55.29M sh | +1.2% | — |
| FY2021 | — | $802.49M | $802.49M | — | 54.64M sh | −21.5% | — |
| FY2020 | — | $0.00 | $0.00 | — | 69.60M sh | +1.6% | — |
| FY2019 | — | $0.00 | $0.00 | — | 68.51M sh | +17.3% | — |
Segments
Products
LineFY2025ShareChange
Product revenue, net$54.03M100%+48.0%
Collaboration revenue – other———
Commercialization Activities———
Committee participation———
Development activities———
Licenses———
Milestone revenue———
On-going research and development services———
Total$54.03M
Pharmaceutical preparations
Agios Pharmaceuticals, Inc. is the 125th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
TNGXTango Therapeutics, Inc.$62.4M48.3%162.9%$4.2BDERMJourney Medical Corp$61.9M10.2%18.5%$123.4MAYTUAytu Biopharma, Inc$57.6M13.3%24.8%$19.4MNKTRNektar Therapeutics$55.2M43.9%297.1%$1.3B
AGIOAgios Pharmaceuticals, Inc. (this company)$54.0M48.0%764.0%$1.9B
QTTBQ32 Bio Inc.$53.7M—55.5%$263.3MOCULOcular Therapeutix, Inc$52.0M18.5%511.9%$1.4BLXRXLexicon Pharmaceuticals, Inc.$49.8M729.9%101.1%$812.6MGOSSGossamer Bio, Inc.$48.5M57.7%351.5%$68.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR